The global HER2-positive breast cancer market is rapidly evolving due to rising prevalence and demand for targeted therapies. HER2-positive breast cancer, characterized by overexpression of HER2 ...

Summit Therapeutics nears a $15B AstraZeneca deal for ivonescimab, targeting a $90B market. See more on the potential and ...

A new once-day pill made by AstraZeneca has the ability to delay breast cancer progression in those in the advanced stages along with ESR1 mutations, according to phase-3 trials conducted by the ...

Datroway is used to treat an advanced form of non-small cell lung cancer in adults who had received prior treatment.

During a live event, Heather L. McArthur, MD, MPH, discussed the TAILORx trial in node-negative hormone ...

Lung cancer proved the second-most discussed cancer type during ASCO 2025, totalling 2,995 mentions by more than 530 HCPs. As ...

AstraZeneca chief executive Pascal Soriot is considering moving the company's stock exchange listing from the UK to the US – ...

Thousands of women battling advanced breast cancer could be denied access to crucial life-extending medication due to an ...

Elinzanetant is the first neurokinin-targeted therapy to demonstrate efficacy in reducing vasomotor symptoms (VMS)” — ...

Cambridge-based AstraZeneca looks like it has set another drug on its way to blockbuster status - Datroway for the treatment ...

The FDA delivered two notable approvals for RSV immunization, UroGen overcame a negative advisory committee vote to secure an ...